A vaccine candidate provided 54% protection against active tuberculosis disease in adults with Mycobacterium tuberculosis infection, according to results from a phase 2b trial published today in The New England Journal of Medicine.
“There were an estimated 10.4 million new cases of tuberculosis and 1.7 million deaths from the disease in 2016,” Olivier Van Der Meeren, MD, director and senior clinical research and development lead for HIV and TB vaccine development at GlaxoSmithKline, and colleagues wrote. “An effective tuberculosis vaccine for M. tuberculosis-infected persons could have a marked effect on tuberculosis control, including drug-resistant tuberculosis, through interruption of transmission.”
This activity is supported by an educational grant from ViiV Healthcare.
Zika Resource Center
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2018 Healio All Rights Reserved.